We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · September 10, 2020

Prasugrel-Based De-Escalation of Dual Antiplatelet Therapy After PCI in Patients With Acute Coronary Syndrome

The Lancet

 

Additional Info

The Lancet
Prasugrel-Based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome (HOST-REDUCE-POLYTECH-ACS): An Open-Label, Multicentre, Non-Inferiority Randomised Trial
Lancet 2020 Aug 28;[EPub Ahead of Print], HS Kim, J Kang, D Hwang, JK Han, HM Yang, HJ Kang, BK Koo, JY Rhew, KJ Chun, YH Lim, JM Bong, JW Bae, BK Lee, KW Park

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading